Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for SLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 38.83M
March 31, 2026 44.15M
December 31, 2025 32.39M
September 30, 2025 26.09M
June 30, 2025 4.23M
March 31, 2025 23.58M
December 31, 2024 0.008M
September 30, 2024 19.69M
June 30, 2024 0.414M
March 31, 2024 26.65M
December 31, 2023 3.386M
September 30, 2023 0.054M
June 30, 2023 -0.029M
March 31, 2023 18.90M
December 31, 2022 0.929M
September 30, 2022 0.107M
June 30, 2022 23.00M
March 31, 2022 0.047M
December 31, 2021 0.05M
September 30, 2021 2.242M
June 30, 2021 6.782M
March 31, 2021 3.00M
December 31, 2020 23.68M
September 30, 2020 8.492M
June 30, 2020 -0.025M
Date Value
March 31, 2020 6.30M
December 31, 2019 2.319M
September 30, 2019 0.189M
June 30, 2019 14.83M
March 31, 2019 2.23M
December 31, 2018 -0.076M
September 30, 2018 14.25M
June 30, 2018 4.208M
March 31, 2018 4.739M
December 31, 2017 -0.12M
September 30, 2017 -0.001M
June 30, 2017 -14.32M
March 31, 2017 19.98M
December 31, 2016 1.569M
September 30, 2016 17.13M
June 30, 2016 -3.628M
March 31, 2016 19.25M
December 31, 2015 -1.009M
September 30, 2015 -0.759M
June 30, 2015 4.329M
March 31, 2015 41.28M
December 31, 2014 9.855M
September 30, 2014 -0.334M
June 30, 2014 0.019M
March 31, 2014 14.72M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Savara, Inc. 0.189M
Lite Strategy, Inc. -1.792M
AbbVie, Inc. -5.054B
Marker Therapeutics, Inc. 0.00
Rezolute, Inc. 0.747M